凯普生物 reported revenue of ¥0.30B for the period ended 2026-06-30, -4.7% year on year. Net income was ¥0.03B, a 8.5% net margin on a 47.3% gross margin. The largest revenue line is 体外诊断试剂、配套仪器和耗材 at 76% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.30B | -4.7% |
| Gross profit | ¥0.14B | — |
| Operating income | ¥0.05B | — |
| Net income | ¥0.03B | — |
| Gross margin | 47.3% | Net margin 8.5% |
| Revenue Q/Q | +38.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 体外诊断试剂、配套仪器和耗材 | ¥0.23B | 76.2% |
| 医学检验服务 | ¥0.12B | 39.7% |
| 医疗服务 | ¥0.02B | 7.0% |
| 分部间抵销 | ¥-0.07B | -22.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.16B | 52.7% |
| R&D | ¥0.03B | 9.4% |
| SG&A | ¥0.14B | 48.1% |
| Tax & other | ¥0.02B | 6.7% |
| Item | Amount |
|---|---|
| Total assets | ¥4.20B |
| Total liabilities | ¥0.48B |
| Shareholders' equity | ¥3.72B |
| Equity / assets | 88.7% |
| Operating cash flow | ¥0.05B |
| Capital expenditure | ¥0.07B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 278% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份 ・ 金陵体育 ・ 雷迪克
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies